Le quote di ricavo sono stime per nine months ended July 31, 2026, non cifre tratte da un documento depositato.
Infinity III liquid chromatography systems
Instruments that separate the substances in a liquid sample so a laboratory can identify and measure them.
8890B and 8860B gas chromatographs
Instruments that separate and measure substances that can be turned into gas, including chemicals in fuels and contaminants in food.
9500 triple-quadrupole inductively coupled plasma mass spectrometer
An instrument that measures very small amounts of metals and other elements, including in samples used in semiconductor manufacturing.
Altura liquid chromatography columns
Replaceable tubes that separate substances inside a chromatography system, including in testing of protein-based and nucleic-acid medicines.
Dako Omnis pathology systems
Automated instruments and related supplies used by clinical laboratories to stain and examine tissue samples for cancer diagnosis.
Oligonucleotide contract manufacturing
Manufacturing of short DNA- or RNA-like drug ingredients for pharmaceutical customers, from development through commercial production.
Agilent makes instruments that help laboratories identify and measure the chemicals, cells and other materials in samples. It also sells the supplies used with those instruments, maintains lab equipment, and provides software for collecting and managing test results. For drug companies, Agilent also makes ingredients used in some medicines and manufactures certain drug materials under contract.
Costruito dai documenti depositati da Agilent Technologies, Inc. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
A · NYSE · Healthcare · Diagnostics and Research
176,91 USD-0,5%chiusura 11 nov
Prossimi risultati: 23 novembre 2026 · dopo la chiusura
Dati fino al 31 luglio 2026, dal 10-Q depositato il 1 settembre 2026
Agilent sells laboratory supplies and maintenance services, plus scientific instruments, to pharmaceutical companies, hospitals, research labs and testing laboratories.
Previsione dell’azienda: ricavi di da 7,5B USD a 7,5B USD per Esercizio 2026 — in crescita del 7,9% sull'anno precedente
The themes Agilent Technologies is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade B+
La fascia sotto il prezzo mostra il voto in ogni data, calcolato solo sui documenti già pubblici in quel momento.
Mostra 2 trimestri su 40 dello storico dei voti di Agilent Technologies, Inc.. Gli altri 38 risalgono fino a dicembre 2016.